- Upper respiratory infections including tonsillitis, pharyngitis, sinusitis, otitis media and scarlet fever.
- Lower respiratory infections including bronchitis, pneumonia, empyema and lung abscess.
- Skin and soft tissue infections including acne, furuncles, cellulitis, impetigo, abscesses, and wound infections, specific skin and soft tissue infections like erysipelas and paronychia (panaritium).
- Bone and joint infections including osteomyelitis and septic arthritis.
- Gynecological infections including endometritis, cellulitis, vaginal cuff infection, tubo-ovarian abscess and salpingitis when given in conjunction with an antibiotic of appropriate gram negative aerobic spectrum. In cases of cervicitis due to Chlamydia trachomatis, single drug therapy with clindamycin has been shown to be effective in eradicating the organism.
- Intra-abdominal infections including peritonitis and abdominal abscess when given in conjunction with an antibiotic of appropriate gram negative aerobic spectrum.
- Septicemia and endocarditis. The effectiveness of clindamycin in the treatment of selected cases of endocarditis has been documented when clindamycin is determined to be bactericidal to the infecting organism by in vitro testing of appropriate achievable serum concentrations.
- Dental infections, such as periodontal abscess and periodontitis.
- Pneumocystis jirovecii (previously classified as Pneumocystis carinii) pneumonia in patients with AIDS. In patients who are intolerant to, or do not respond adequately to conventional treatment, clindamycin may be used in combination with primaquine.
- Malaria. For this indication, please refer to latest guidelines of diagnostic and treatment for malaria issued by Ministry of Health.
- Prophylaxis of endocarditis in patients sensitive/allergic to penicillin(s).
300 mg/time every 6, 8, 12 hours or 600 mg/time every 8, 12 hours.
- Children are able to swallow capsules
8 – 25 mg/kg/day divided into three or four equal doses. The use of capsules may not be suitable to provide the exact mg/kg doses required for the treatment of children; therefore, use of suitable dosage forms is recommended in the other cases.
Clindastad 150 capsules should not be used for children who are unable to swallow capsules.
Pharmacokinetic studies with clindamycin have shown no clinically important differences between young and elderly subjects with normal hepatic function and normal (age-adjusted) renal function after oral or intravenous administration. Therefore, dosage adjustments are not necessary in the elderly with normal hepatic function and normal (age-adjusted) renal function.
- Clindamycin dosage modification is not necessary in patients with renal and hepatic insufficiency.
- Treatment of Beta-Hemolytic Streptococcal infections:
Refer to the dosage recommendations above under Adults, Children. Treatment should be continued for at least 10 days.
- Treatment of Chlamydia trachomatis cervicitis:
Clindamycin hydrochloride capsules orally 600 mg, 3 times daily for 10 – 14 days.
- Treatment of Pneumocystis jirovecii pneumonia in patients with AIDS:
Clindamycin hydrochloride 300 mg every 6 hours or 600 mg every 8 hours orally for 21 days and primaquine 15 to 30 mg dose orally once daily for 21 days.
- Treatment of acute streptococcal tonsillitis/pharyngitis:
Clindamycin hydrochloride capsules 300 mg orally twice daily for 10 days.
- Treatment of malaria:
For this indication, please refer to latest guidelines of diagnostic and treatment for malaria issued by Ministry of Health.
- Prophylaxis of endocarditis in patients sensitive to penicillin:
Adults: 600 mg 1 hour before procedure; children: 20 mg/kg 1 hour before procedure.
Clindastad 150 is administered orally.
To avoid the possibility of esophageal irritation, clindamycin hydrochloride capsules should be taken with a full glass of water.